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Abstract 26 
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are 27 
incretin hormones released from intestinal enteroendocrine (EE) cells and have well-28 
established glucose-lowering actions. Lactic acid bacteria (LAB) colonise the human 29 
intestine but it is unknown whether LAB and EE cells interact. Acute co-culture of LAB with 30 
EE cells showed that certain LAB strains elicit GLP-1 and GIP secretion (13-194-fold) and 31 
upregulate their gene expression. LAB-induced incretin hormone secretion did not appear to 32 
involve nutrient mechanisms, nor was there any evidence of cytolysis. Instead PCR array 33 
studies implicated signalling agents of the toll-like receptor system, e.g. adaptor protein 34 
MyD88 was decreased 23-fold and cell surface antigen CD14 was increased 17-fold. 35 
Mechanistic studies found that blockade of MyD88 triggered significant GLP-1 secretion. 36 
Furthermore, blocking of CD14 completely attenuated LAB-induced secretion. A recent 37 
clinical trial clearly shows that LAB have potential for alleviating type 2 diabetes and further 38 
characterisation of this bioactivity is warranted.  39 
 40 
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 42 
43 
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1. Introduction  44 
The incretin hormones are gastrointestinal insulin-releasing peptides involved in the 45 
regulation of postprandial nutrient homeostasis. Postprandial release of these hormones forms 46 
part of the entero-insular axis which contributes significantly to normal glucose homeostasis, 47 
particularly in the period following the consumption of a meal (Flatt & Green, 2006; Baggio 48 
& Drucker, 2007; Green et al., 2005). The two established incretin hormones are glucagon-49 
like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and they are 50 
produced by enteroendocrine (EE) cells lining the intestine. GLP-1 is produced by intestinal 51 
L-cells which are at the highest densities in the distal small intestine and colon. GIP is 52 
produced and secreted by K-cells which are predominantly located in the proximal small 53 
intestine (Baggio & Drucker, 2007). It is also evident that EE cells with an L/K phenotype 54 
exist and a shift of the intestinal cell population towards this type has been associated with 55 
the prevention of beta-cell loss and hyperglycaemia in diabetic animal models (Speck et al., 56 
2011).  The incretin hormones have been the basis for a number of clinically approved 57 
pharmaceutical compounds with good efficacy for the treatment of human type 2 diabetes 58 
and its complications (Neumiller, 2012; Tate et al., 2015]. Importantly their use has been 59 
associated with low risk of hypoglycaemia and good tolerability and safety.  60 
 A novel and perhaps more radical approach involves the discovery of gut probiotic 61 
organisms capable of modulating the incretin hormone system (Yadav et al., 2013; Forssten 62 
et al., 2013; Duan, Liu, & March, 2015). Probiotic bacteria routinely come into close 63 
proximity with the intestinal lining allowing the possibility that either they or their bacterial 64 
metabolites could stimulate the secretion of incretin hormones from enteroendocrine cells. 65 
Lactobacilli are present in the small intestine, although cell densities (104 to 108cfu/g) are 66 
lower than in the large intestine (1012-14 cfu/g) (Ley, Peterson, & Gordon, 2006; Walter & 67 
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Ley, 2011).  Gut microbiota are diverse and abundant constituting approximately 1014 (100 68 
trillion) cells in an individual person (Ley, Peterson, & Gordon, 2006).  They contribute 69 
significantly to human nutrition and health (Flint et al., 2012) playing roles in immunity 70 
(Hardy et al., 2013; Kelly & Mulder, 2012), the fulfilment of dietary amino acid requirements 71 
(Walter & Ley, 2011) and they impact on energy balance (Molinaro et al., 2012; Cani et al., 72 
2012). Besides these physiological effects, interaction with gut epithelial surface elicits 73 
several signalling pathways (Audy et al., 2012; Giahi et al., 2012) that are responsible for 74 
regulation of the aforementioned functions. Probiotic-based dietary intervention has been 75 
proposed for the alleviation of various clinical conditions including gastrointestinal disorders 76 
(Horvath & Szajewska, 2013; Hijova & Soltesova, 2013), ulcerative colitis (De Greef et al., 77 
2013; Dylag et al., 2014), necrotizing enterocolitis (Liu et al., 2013), respiratory disorders 78 
(Forsythe, 2011) and allergies (Prakash et al., 2013; Castellazzi et al., 2013). The proposed 79 
use of probiotics for the alleviation of diabetes and/or obesity is unestablished but is a hotly 80 
debated topic (27-29, 9 Sanz, Santacruz, & Gauffin, 2010; Ejtahed et al., 2012;  Panwar et al., 81 
2014; Duan, Liu, & March, 2015).  82 
The aim of this study was to probe the ability of one genus of lactic acid bacteria 83 
(LAB) to modulate the secretion and gene expression of the incretin hormones in EE cells. 84 
The strains investigated included Lactobacillus isolates originating from human infant faeces 85 
and a number of Lactobacillus reference cultures. For each strain we examined how co-86 
culture with pGIP/Neo STC-1 cells affected GLP-1 secretion, GIP secretion, as well as, 87 
changes in the expression of proglucagon (the precursor of GLP-1) and GIP genes. The most 88 
promising Lactobacillus organism was then used to investigate possible mechanisms through 89 
which it exerted effects on EE cells.  90 
2. Materials and methods 91 
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2.1 Chemicals and reagents 92 
De Man, Rogosa and Sharpe (MRS) broth (M369) was obtained from HiMedia Laboratories 93 
(Mumbai, India). Mueller-Hinton broth (CM0405) from Oxoid (Hampshire, UK). Dulbecco’s 94 
Modified Eagle’s Medium (DMEM) containing 4.5 g/l D-glucose, without sodium pyruvate 95 
(GlutaMAX) was obtained from GIBCO, Paisley, UK. Penicillin, streptomycin and geneticin 96 
(G418) were purchased from Sigma (Poole, Dorset, UK). Radioiodinated GLP-1 was 97 
obtained from Perkin Elmer (Waltham, MA, USA). GIP ELISA kits were purchased from 98 
Millipore (Billerica, MA, USA).  Cytotoxicity Detection Kit PLUS (LDH) kits were 99 
purchased from Roche Diagnostics Ltd (West Sussex, UK). 100 
2.2 Isolation, culture and Identification of Lactobacillus strains 101 
Faecal samples were collected from five healthy breast-fed infants <9 months in age living in 102 
Shamli, Uttar Pradesh, India. In each case parental consent was obtained. Lactobacillus 103 
cultures were isolated from faecal samples of healthy human infants (Lb1-15; Table 1).  104 
Lactobacillus reference strains (Ref1-7; Table 1) and a Gram positive control 105 
(Bifidobacterium bifidum; Ctrl1; Table 1) were obtained from the National Collection of 106 
Industrial, Food and Marine Bacteria (Aberdeen, UK). E. coli K12 (Ctrl 2; Table 1) was 107 
procured from National Collection of Type Cultures (NCTC) (Colindale, London). Identity of 108 
Lactobacillus isolates was determined to genus level by PCR using a genus-specific primer 109 
pair (Table 2). Amplified products (Table 2; 1400bp for 16SrRNA and 600bp for Phe) were 110 
sequenced using an external DNA sequencing service (DNA Sequencing and Services, 111 
University of Dundee, UK). 112 
In preparation for experiments bacterial cultures were grown overnight (37oC) in their 113 
respective media (10 ml), harvested (12,000g, 15min, 10oC) and washed twice with 1X PBS. 114 
Cell pellets were again re-suspended in 1X PBS and diluted to O.D600 1.5 which 115 
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corresponded to 1×109 cfu/mL of viable cells as determined by standard viable count method 116 
(Wehr & Frank, 2004). One millilitre of bacterial culture at O.D600 1.5 was pelleted down and 117 
re-suspended in 600 µl of freshly prepared HEPES buffer (pH7.4) for co-culture with 118 
pGIP/Neo STC-1 cells.  119 
2.3 Cell Culture  120 
pGIP/Neo STC-1 cells were a gift from Dr. B. Wice (Washington University of St. 121 
Louis) (Ramshur, Rull, & Wice, 2002) with permission from Dr D. Hanahan (University of 122 
California, San Francisco, CA). pGIP/Neo STC-1 cells are a GIP enriched sub-clone of 123 
heterogeneous pluripotent murine STC-1 cells. The cell line secretes measurable amounts of 124 
GLP-1 and GIP, retains secretory function and is responsive to various stimuli (Gillespie et 125 
al. 2015; Jafri et al. 2016). Cells were cultured as previously described (Hand, Giblin, & 126 
Green, 2012; Rafferty et al., 2011). Briefly, they were maintained in a humidified incubator 127 
at 37°C and 5% CO2 DMEM containing 4.5 g/L with L-glutamine, without sodium pyruvate 128 
(Life Technologies, Paisley, UK) and supplemented with 10% foetal bovine serum, 100 129 
U/mL penicillin, 100 mg/L streptomycin and geneticin - G418, 400 μg/mL. Cells were 130 
trypsinised at 70-80% confluency and seeded in flasks or plates as required, and only used 131 
between 20-50 passages.   132 
Light microscopy of L. rhamnosus and pGIP/Neo STC-1 cells was carried out by 133 
fixing with methanol (10 min at room temperature), removing methanol, staining with crystal 134 
violet  for 30s and washing twice immediately with PBS buffer. Plates were allowed to air 135 
dry and viewing using a confocal light microscope (Nikon, Surrey, UK).  136 
2.4 GLP-1 and GIP secretion studies 137 
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 For hormone secretion and gene expression studies approximately 2x106 pGIP/Neo 138 
STC-1 cells were seeded into 12-well plates with DMEM and allowed to attach overnight 139 
(37oC; 5% CO2), media was removed and cells were washed (3 times; HEPES buffer) 140 
(Mccarthy et al., 2015). Cells were pre-incubated in 1 ml of HEPES buffer for 1h. Buffer was 141 
removed and cells were co-cultured with 2x109 live bacteria for 3h (37oC; 5% CO2). Cell 142 
supernatant (HEPES Buffer) was aspirated and collected in a fresh tube, placed on ice and 143 
centrifuged (5000g, 5 min) to remove any cellular debris. Supernatant was collected and 144 
stored at -70oC prior to GLP-1 and GIP immunoassays. mRNA was isolated from cells using 145 
a commercial RNeasy Mini Kit (Quigen, Manchester, UK). Additional GLP-1 secretion 146 
studies (3h; 37oC; 5%CO2) were performed with a mixture of L-alanine (20 nmol/L), L-147 
histidine (20 nmol/L) and L-proline (10 nmol/L). Studies were also conducted with L. 148 
rhamnosus (2x109 CFU/mL) alone or in combination with either a Myd88 blocking peptide 149 
(50µM; Pepinh-MYD, Invivogen, Toulouse, France), or an anti-CD14 antibody (anti-mouse 150 
IgG, Cambridge Biosciences, Cambridge, UK).  To ensure that hormone measurements were 151 
not the result of cytolysis the release of lactate dehydrogenase (LDH) was measured in a 152 
series of experiments where, 1010, 109, 108, 107 or 106  LAB were co-cultured with 2x106 153 
pGIP/Neo STC-1 cells for 3h. No cytolysis was detected. GIP concentrations were 154 
determined by commercial competitive ELISA kit (Phoenix pharmaceuticals, Inc. California, 155 
USA) by following the manufacturer’s instructions. GLP-1 concentrations were measured 156 
using an in-house fully optimised radioimmunoassay which used anti-rabbit IgG Sac-Cel 157 
(IDS, Boldon, UK) and had zero cross-reactivity with glucagon or GIP. GLP-1 and GIP 158 
secretion studies were performed in triplicate.  159 
2.5 Amino acid analysis 160 
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Samples of test buffer (3 ml) were spiked with 0.3 ml Norleucine (1.5 mg/ml; internal 161 
standard) and mixed in ddH2O (10ml) for 1 min. Samples were then centrifuged (3,500g, 162 
4°C, 25 min) and the supernatant collected. Pellets were re-suspended in ddH2O (5 ml), 163 
centrifugation was repeated and both supernatants were combined. The supernatant (500 µl) 164 
was filtered through a molecular weight cut off filter (Vivaspin, MWCDO 3000, Sigma) with 165 
centrifugation at 3,500g for 90 min at 4°C.  The filtered sample (100 µl) was analysed using 166 
an Agilent GC (model 7890, Delaware, USA) coupled to an MS detector (Agilent model 167 
5975C, Delaware, USA) in combination with an amino acid analysis kit (EZ:faast; 168 
Phenomenex, Cheshire, UK).  169 
2.6 Gene expression studies and real time PCR array 170 
 SYBR green Quantitative real-time PCR was used to determine changes in gene 171 
expression with β-actin used as a reference gene to normalise data. RNA quality and quantity 172 
were checked by nanodrop/spectrophotometric (260/280) analysis and gel electrophoresis 173 
(1% agarose), respectively. RNA (1µg) was converted to cDNA using commercial 174 
QuantiTect Reverse Transcription Kit (Qiagen) and was quantified using nanodrop. cDNA 175 
was diluted to working dilution of 30ng/µl by dissolving in nuclease free water. Primer 176 
sequences for proglucagon (GLP-1), GIP, β-actin, GPR40, GPR 41 and GPR 120 can be 177 
found in Table 2. RT2 Profiler PCR arrays were used to detect the expression of 84 genes 178 
implicated in regulating TLR pathways.  For PCR array, RNA was further purified using 179 
SABiosciences RT2 qPCR-Grade RNA Isolation Kit according to the manufacturer’s 180 
protocol. RNA quality was analysed and met the required criteria for Real-time PCR arrays. 181 
Mouse TLR PCR array kits were purchased from Qiagen (RT ProfilerTM PCR Array Mouse 182 
Toll-Like Receptor Signalling Pathway [PAMM-018A-2]). The kit profiles the expression of 183 
84 genes (n=2 biological replicates) related to TLR-mediated signal transduction and five 184 
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housekeeping genes (GUSB, HPRT1, HSP90ab1, GADPH and ACTB). A negative control 185 
for genomic DNA and contaminating RNA was also conducted in each sample. 186 
Amplification, data acquisition, and the melting curve were carried out using a Mastercycler 187 
ep Realplex (Eppendorf, Stevenage, UK). The PCR cycling program was set as follows: stage 188 
1: 95°C for 10 min, stage 2: 95°C for 15 sec followed by 60°C for 1 minute repeated for 40 189 
cycles, and stage 3: 95°C for 15 sec, 60°C for 15 sec and 95°C for 15 sec. The cycle 190 
threshold (Ct) and melting curve of each gene were established and recorded by the software. 191 
The delta Ct (ΔCt) method was used for PCR array data analysis. The normalized ΔCt for 192 
each gene of interest (GOI) was calculated by deducting the average Ct of the 5 housekeeping 193 
genes (HKG) from the Ct of each gene of interest. Then the double delta Ct (ΔΔCt) for each 194 
gene of interest was calculated by deducting the average ΔCt in the control group from the 195 
ΔCt of each gene of interest. The fold-change of each GOI compared to the sham group was 196 
calculated as 2-ΔΔCt. 197 
2.7 Data analysis 198 
Graphs were produced and statistically analysed using Graph pad Prism (Version 6, 199 
La Jolla, CA, USA). Bar graphs display mean ± SEM. A heat map of PCR array data was 200 
generated (MetATT) which employed mean centred data normalisation.  201 
3. Results  202 
3.1 GLP-1 and GIP secretion following Lactobacillus co-culture  203 
Co-culture of a number of Lactobacillus strains with pGIP/Neo STC-1 cells elicited 204 
significant GLP-1 secretion which was not associated with cytotoxicity or cytolysis.  Cells 205 
incubated in a non-stimulatory vehicle control secreted 4.5±0.5 pM/106 cells/h whereas 3h 206 
co-culture with faecal isolate, Lb3 (later identified as Lactobacillus plantarum subsp. 207 
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argentorotensis; KC491380) secreted 86.8±6 pM/106 cells/h (Figure 1A). For GIP, secretion 208 
of 1.9±0.05 pM/106 cells/h occurred with a non-stimulatory vehicle control. Two faecal 209 
isolate strains: Lb1 (later identified as being Lactobacillus plantarum) and Lb3 stimulated 210 
significant GIP secretion (Figure 1B; 100.6±2.9 and 155.8±24.9 pM/106 cells/h, respectively.  211 
Co-culture with two reference strains L. johnsonii (NCIMB8795) and L. rhamnosus 212 
(NCIMB6375) significantly increased both GLP-1 secretion (Figure 1A; 61.0±8.4 and 213 
82.3±26.1 pM/106 cells/h, respectively) and GIP secretion (Figure 1B; 369.5±68.9 and 214 
285.7±34.7 pM/106 cells/h, respectively). The Gram positive (B. bifidum) and Gram negative 215 
(E. coli) control organisms did not stimulate any incretin hormone secretion.  216 
 217 
3.2 Changes in incretin hormone gene expression following Lactobacillus co-culture 218 
A number of Lactobacillus strains affected the levels of gene expression of 219 
proglucagon and GIP in pGIP/Neo STC-1cells. Two Lactobacillus isolates Lb4 and Lb6 220 
(both identified as Lactobacillus plantarum) upregulated proglucagon gene expression 3.6- 221 
and 2.5-fold, respectively (Figure 2A). Four reference strains L. acidophilus 222 
(NCIMB701748), L. casei (NCIMB4114), L. plantarum (NCIMB1406) and L. rhamnosus 223 
(NCIMB6375) significantly increased proglucagon gene expression (Figure 2A; 2.9-, 1.8-, 224 
1.9- and 2.9-fold, respectively). Interestingly, B. bifidum up-regulated GLP-1 proglucagon 225 
gene expression 2.1-fold. Four Lactobacillus isolates Lb4, Lb6, Lb8 and Lb9 (all 226 
Lactobacillus plantarum) along with three reference cultures (L. casei, L. plantarum and L. 227 
rhamnosus) significantly up-regulated GIP gene expression (Figure 2B; 2.5-, 2.7-, 2.3, 2.2-, 228 
2.4-, 3.2- and 5.4-fold, respectively). The Gram-negative bacterium E. coli did not affect 229 
either proglucagon or GIP gene expression.  230 
3.3 Nutrient-related mechanisms involved in Lactobacilli-stimulated GLP-1 secretion 231 
 11 
 
As a particularly potent enhancer of GLP-1/GIP secretion and gene expression L. 232 
rhamnosus was selected for further studies. Changes in the amino acid composition of the test 233 
buffer were examined by GC-MS (Figure 3A) which indicated that there was a significant 234 
increase in the levels of L-alanine, L-proline and L-Histidine. However, a combination of 235 
these three amino acids failed to stimulate GLP-1 secretion in STC-1pGIP/Neo cells (Figure 236 
3B). The effects of L. rhamnosus co-culture on the expression of free fatty acid (FFA) 237 
receptors (GPR40, 41 and 120) were examined. These were compared against L. casei, which 238 
did not stimulate incretin hormone secretion but did alter incretin gene expression. L. 239 
rhamnosus modestly increased the expression of GPR40 (2.4±1.4-fold) and decreased 240 
GPR120 (0.4±0.01-fold) and had no effect on GPR41. By comparison L. casei upregulated 241 
GPR-40 by 6.7±1 and GPR-41 by 28.0±4 fold and left GPR120 unchanged. The isolate Lb-3 242 
was also examined (data not shown) and it did not affect the expression of any of the three 243 
FFA receptors.  244 
3.4 Molecular mechanisms involved in Lactobacilli-stimulated GLP-1 secretion 245 
Confocal light microscopy (Figure 4A) demonstrated that L. rhamnosus cells (purple) 246 
are closely localised to pGIP/Neo STC-1 cells (blue), perhaps even adhering to the cell 247 
surface. A mouse PCR array examined the effect of L. rhamnosus co-culture on the 248 
expression of 84 genes related to Toll-like receptor signalling pathways (Figure 4B). A full 249 
list of the genes affected can be found in Supplementary Table 1. Whilst up-regulation in the 250 
expression of some genes was evident the majority were down-regulated following L. 251 
rhamnosus co-culture (Figure 4B). Some of the most profound changes in expression 252 
occurred in genes identified as “Adaptors & Interacting Proteins” (Supplementary Table 1). 253 
Most notably CD14 expression was up-regulated most (17.5-fold) and Myd88 was down-254 
regulated greatest (23.4-fold). The application of the MyD88 blocking peptide (Pepinh-255 
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MYD) alone evoked a significant GLP-1 secretory response (Figure 4C; 2.3-fold; P<0.001), 256 
but Pepinh-MYD did not significantly affect L. rhamnosus-stimulated GLP-1 secretion. No 257 
GLP-1 secretory responses were evident when an antibody directed against the cell surface 258 
antigen CD14 (anti-CD14) was applied alone or in combination with L. rhamnosus (Figure 259 
4C).  260 
4. Discussion 261 
This study is the first to demonstrate that lactic acid bacteria can interact with 262 
physiologically important intestinal cells.  The EE cells collectively constitute the largest 263 
endocrine system in the body, producing and secrete a range of different gastrointestinal 264 
hormones. Co-culturing of EE cells with various Lactobacillus strains/isolates clearly 265 
affected the extent to which the cells secrete and express the incretin hormones. We have 266 
identified novel bacterial isolates which modulate the secretion and expression of both GLP-1 267 
and GIP. For example L. plantarum subsp. argentorotensis (Lb3) which triggered potent 268 
GLP-1 and GIP secretion in pGIP/Neo STC-1 cells. Various isolates identified as strains of L. 269 
plantarum (i.e. Lb1, 4, 6, 8, and 9), along with the corresponding reference culture (Ref6), 270 
positively influenced either incretin hormone secretion or incretin gene expression (but not 271 
both simultaneously). 16S rRNA sequencing revealed none of the L. plantarum isolates to be 272 
genetically identical, which may explain why their effects on EE cells were inconsistent. 273 
Indeed there were some L. plantarum isolates (e.g. Lb2, Lb5) which had no impact on 274 
incretin secretion or expression.  275 
There were similar observations with L. acidophilus where the isolate Lb15 had no 276 
appreciable effects, yet the corresponding reference culture (Ref 1) significantly up-regulated 277 
proglucagon gene expression. The reference culture of L. johnsonii showed particularly 278 
promising effects on incretin hormone secretion but did not affect gene expression. Only the 279 
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reference culture of L. rhamnosus positively influenced all four incretin hormone parameters 280 
which prompted us to select it for further investigation. It is well established that incretin 281 
hormone secretion can be stimulated by the presence of either amino acids or fatty acids in 282 
the lumen of the intestine (Baggio & Drucker, 2007). Therefore, we examined whether L. 283 
rhamnosus was influencing GLP-1 secretion through a nutrient-based mechanism. The 284 
bacterial metabolism of L. rhamnosus appeared to elevate the levels of three amino acids (L-285 
alanine, L-proline and L-histidine) in the test buffer, yet when tested these amino acids did 286 
not stimulate GLP-1 secretion. It is well known that Lactobacillus spp. (including L. 287 
rhamnosus) can produce various fatty acids, most notably short-chain fatty acids (SCFAs) 288 
such as butyrate (Umeki et al., 2004; Licciardi et al., 2010). Fatty acids are known to be 289 
secretagogues of GLP-1 and GIP. We found that FFA receptor expression (GPR40, 41 and 290 
120) in EE cells was affected by co-culture with lactobacilli.  L. rhamnosus modestly 291 
increased mRNA transcripts of one medium/long chain FFA receptor (GPR40) but reduced 292 
that of another medium/long chain FFA receptor (GPR120). However, it was clear that L. 293 
rhamnosus did not affect the expression of the SCFA receptor GPR41 and when measured 294 
the levels of butyrate in the culture medium were unaffected (data not shown) indicating that 295 
production of SCFAs was unlikely to be responsible for observed effects on EE cells. There 296 
is a potential limitation in this study - that changes in other FA receptors expressed on 297 
enteroendocrine cells (such as GPR119 for example) were not examined. A role for 298 
medium/long chain fatty acids cannot be completely ruled out, however, it is clear that L. 299 
casei (which is devoid of incretin secretory activity) had more profound effects than L. 300 
rhamnosus on FFA receptor expression (i.e. GPR40 and 41).  301 
In a separate phase of studies we attempted to ascertain whether L. rhamnosus could 302 
be influencing GLP-1 secretion through its direct interaction with the EE cell surface. This 303 
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was prompted by the observation that in co-culture the majority of L. rhamnosus cells closely 304 
co-localise with pGIP/Neo STC-1 cells, even when cells were seeded at lower densities. We 305 
thought that the most logical mechanism for a bacterial-mammalian cell interaction was 306 
through the toll-like receptor (TLR) family of pattern recognition receptors which detect a 307 
wide range of exogenous factors including bacteria, viruses, fungi and parasites (Kamdar, 308 
Nguyen, & DePaolo, 2013). A qPCR array measuring the expression of 84 TLR-related genes 309 
(See Supplementary Table 1) was performed. This produced quite startling results – there was 310 
a broad (but not exclusive) down-regulation of the genes in the TLR family, some of which 311 
were reduced by more than 20-fold. TLR2 and TLR4 receptors were significantly down-312 
regulated, but some of the biggest changes were in the expression of adaptor proteins 313 
involved in TLR signalling. These included the cell surface antigen CD14 which was 314 
increased almost 18-fold and the adapter protein MyD88 which was decreased 23-fold.  315 
These two proteins were tentatively investigated for their potential involvement in L. 316 
rhamnosus-induced stimulation of GLP-1 secretion. Interestingly, we found that the addition 317 
of pepinh-MYD (which blocks the homo-dimerisation of MyD88) alone caused significant 318 
GLP-1 secretion. Importantly pepinh-MYD did not have an additive effect on L. rhamnosus-319 
induced GLP-1 secretion.  This finding suggests that down-regulation of MyD88 320 
expression/activity leads to higher levels of GLP-1 secretion, although it cannot be 321 
definitively stated that this is the precise mechanism for L. rhamnosus-stimulated GLP-1 322 
secretion.  We also found that the application of an antibody directed against murine CD14 323 
alone had no effect on GLP-1 secretion but it significantly attenuated L. rhamnosus-324 
stimulated secretion. CD14 plays a key role in initiating cell activation by a range of 325 
bacterially-derived molecules, such as the lipopolysaccharides from Gram-negative bacteria 326 
and peptidoglycans from Gram-positive and Gram-negative bacteria (Dziarski, Tapping, & 327 
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Tobias, 1998). It could be postulated that CD14 is a surface antigen which facilitates 328 
adhesion of L. rhamnosus peptidoglycans to the EE cell surface, but the exact signalling role 329 
(if any) for eliciting incretin hormone secretion clearly requires further investigation. CD14 is 330 
best characterised as a feature of monocytes and macrophages with most subpopulations of 331 
these cells expressing CD14. The interaction of commensal bacteria with the gut lining is an 332 
incredibly understudied area and there is presently very little scientific literature elucidating 333 
the role of CD14 in the intestine.  It ha s been shown however, that an E. coli probiotic 334 
organisms used in the treatment of inflammatory bowel disorders stimulated the gene 335 
expression of CD14 in the Caco-2 intestinal epithelial cell line (Hafez et al., 2010).  Although 336 
this study did also report that the expression of the adaptor molecules MyD88 and Ticam1 337 
(TRIF) was up-regulated which differs from the present study (Hafez et al., 2010).  338 
 Currently, the investigation of the functional and physiological actions of probiotics is 339 
an extremely active research field, and many health benefits are proposed including the 340 
improvement of gastrointestinal function and lowering of blood cholesterol levels 341 
(Macfarlane & Cummings, 1999). Their incorporation into fermented and non-fermented 342 
dairy products is well accepted, and their inclusion in functional foods such as e.g. fruit 343 
juices, breakfast cereals, cereal bars, etc. has also been investigated. There is growing support 344 
for the concept of utilising probiotic organisms as a dietary prophylactic or therapeutic 345 
strategy for type 2 diabetes mellitus (Yadav et al. 2013; Panwar et al., 2014; Panwar et al., 346 
2016).  The concept has been demonstrated in a recent clinical trial which found that 347 
administration of the probiotic L. reuteri increased insulin secretion and incretin release in 348 
humans (Simon et al., 2015). This group concluded that since L. reuteri did not modulate 349 
faecal microbiota it is likely that Lactobacillus spp. have a direct effect on host physiology – 350 
a proposition which this study supports.  351 
 16 
 
5. Conclusion  352 
In conclusion, this study has shown that there is considerable potential to increase 353 
endogenous GLP-1 and GIP secretion using naturally-occurring commensal bacteria. Our 354 
findings demonstrate that there are cell-to-cell interactions between human commensal 355 
bacterial and EE cells, and that the adaptor proteins of the TLR system are one plausible 356 
signalling mechanism. The underlying protein interactions of specific Lactobacilli with EE 357 
cells should be investigated including the profound changes observed in MyD88 and CD14 358 
expression. The precise role of these proteins in triggering LAB-induced secretion needs to 359 
be elucidated. A limitation of the study is that it focused only on  Lactobacillus spp.  and the 360 
contribution of the many other species of commensal bacteria needs to be investigated.  361 
Probiotic organisms represent a novel therapeutic strategy for type 2 diabetes but it will be 362 
necessary to undertake dietary intervention studies involving safe, well-characterised and 363 
commercially available probiotic stains.  364 
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Figures Legends  537 
 538 
Figure 1 Co-culture of enteroendocrine cells with Lactobacillus strains stimulates 539 
incretin hormone secretion. Graphs show effects of 15 Lactobacillus isolates (Lb1-15), 7 540 
Lactobacillus reference cultures, a Gram positive control (B. bifidum) and a Gram negative 541 
control (E. coli) on the secretion of (A) GLP-1 and (B) GIP in pGIP/Neo STC-1 cells 542 
following 3h co-culture. Data represent means ± SEM (n=6) and statistical significance is 543 
indicated (*P <0.05 and ***P<0.001 compared with control; One-way ANOVA).  544 
 545 
Figure 2 Co-culture of enteroendocrine cells with Lactobacillus strains upregulates 546 
incretin hormone gene expression. Graphs show effects of 15 Lactobacillus isolates (Lb1-547 
15), 7 Lactobacillus reference cultures, a Gram positive control (B. bifidum) and a Gram 548 
negative control (E. coli) on the gene expression of (A) proglucagon (the precursor for GLP-549 
1) and (B) GIP in pGIP/Neo STC-1 cells following 3h co-culture. Data represent means ± 550 
SEM (n=6) and statistical significance is indicated (**P <0.01 and ***P<0.001 compared 551 
with control; One-way ANOVA). 552 
 553 
Figure 3 Possible metabolite-based mechanisms responsible for Lactobacillus-stimulated 554 
incretin hormone secretion. L. rhamnosus was selected for further studies due to its ability 555 
to potently stimulate both GLP-1 and GIP secretion. (A) Changes in amino acid composition 556 
of buffer were identified by GC-MS. (B) Exposure of pGIP/Neo STC-1 cells with the 3 557 
elevated amino acids (alanine, histidine and proline) did not influence GLP-1 secretion. (C) 558 
Changes in free fatty acid receptor gene expression were examined following L. rhamnosus 559 
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co-culture and compared against vehicle control and L. casei (a Lactobacillus strain which 560 
did not stimulate incretin hormone secretion but did influence incretin gene expression. Data 561 
represent means ± SEM (n=3)  and statistical significance is indicated (*P <0.05 and 562 
***P<0.001 compared with control; ns- not significant; One-way ANOVA). 563 
 564 
Figure 4 Other molecular mechanisms possibly involved Lactobacillus-stimulated 565 
incretin hormone secretion. (A) Confocal light microscopy (x400) indicated that many 566 
L.rhamnosus organisms (black) are closely localised to pGIP/Neo STC-1 cells (blue), perhaps 567 
adhering to the cell surface. (B) Toll-like receptor signalling pathways were probed using a 568 
mouse TLR PCR array which demonstrated that a large number of these genes were 569 
downregulated following L rhamnosus co-culture (also see Supplementary Table 1). CD14 570 
expression was up-regulated most (17.5-fold) and Myd88 was down-regulated most (23.4-571 
fold). (C) Application of a My88 blocking peptide or an antibody directed against the cell 572 
surface antigen CD14 significantly affected GLP-1 secretion. Data represent means ± SEM 573 
(n=3)  with *P <0.05 and ***P<0.001 compared with control; ∆∆P<0.01; ∆∆∆P<0.001 574 
compared with L.rhamnosus; One-way ANOVA). 575 
576 
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Figure 2 580 
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 Strain 
code 
Type  Identification %  
Sequence 
Similarity 
Accession or culture 
collection no. 
1 Lb1 Faecal isolate  Strain of Lactobacillus plantarum 98 % Unknown 
2 Lb2 Faecal isolate Strain of Lactobacillus plantarum 99 % Unknown 
3 Lb3 Faecal isolate Lactobacillus plantarum subsp. argentorotensis 99 % KC491380 
4 Lb4 Faecal isolate  Strain of Lactobacillus plantarum 99 %  KF678450 
5 Lb5 Faecal isolate Strain of Lactobacillus plantarum 95 % Unknown 
6 Lb6 Faecal isolate Strain of Lactobacillus plantarum 96 % Unknown 
7 Lb7 Faecal isolate  Strain of Lactobacillus fermentum 98 % Unknown 
8 Lb8 Faecal isolate Strain of Lactobacillus plantarum 99 % KF678451 
9 Lb9 Faecal isolate Strain of Lactobacillus plantarum 99 % KF678452 
10 Lb10 Faecal isolate  Strain of Lactobacillus plantarum 99 % KF678453 
11 Lb11 Faecal isolate Strain of Lactobacillus plantarum 99 % Unknown 
12 Lb12 Faecal isolate  Lactobacillus sp.  99 % Unknown 
13 Lb13 Faecal isolate  Strain of Lactobacillus fermentum 97 % KC866340 
14 Lb14 Faecal isolate Strain of Lactobacillus plantarum 99 % Unknown 
 35 
 
 
 
 
 
 
 
 
 
Table 1. List of bacterial strains examined in the study. Bacterial strains Lb-1 to Lb15 were isolated from faeces from healthy human infants. 
Reference strains (Ref1-7) were obtained from NCIMB. n/a- not applicable. 
15 Lb15 Faecal isolate Strain of Lactobacillus acidophilus 99 % Unknown 
16 Ref1 Reference culture Lactobacillus acidophilus n/a NCIMB701748 
17 Ref2 Reference culture Lactobacillus casei n/a NCIMB4114 
18 Ref3 Reference culture Lactobacillus fermentum n/a NCIMB2797 
19 Ref4 Reference culture Lactobacillus johnsonii n/a NCIMB8795 
20 Ref5 Reference culture Lactobacillus paracasei n/a NCIMB1407 
21 Ref6 Reference culture Lactobacillus plantarum n/a NCIMB1406 
22 Ref7 Reference culture Lactobacillus rhamnosus n/a NCIMB6375 
23 Ctrl1 Gram positive control Bifidobacterium bifidum n/a NCIMB702715 
24 Ctrl2 Gram negative control Escherichia coli n/a NCTC 10538 
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Table 2 Primer sequences used in this study 
Target Forward Reverse Reference 
Proglucagon 
(GLP-1) 
Proglucagon-F   
5’- ggcacattcaccagcgactac -3’, 
Proglucagon-R  
5’- caatggcgacttcttctggg -3’ 
Rasouli et al.,2011 
GIP  GIP-F   
5’- gaagacctgctctctgttgctggt -3’ 
GIP-R  
5’- cagagctctgcttggtccaccatc -3’ 
Jepeal et al., 2008 
β-actin  β-actin-F  
5’- gtgtgatggtgggaatgggtc -3’ 
β-actin-R  
5’- aggaagaggatgcggcagtg -3’ 
Rasouli et al.,2011 
GPR40  GPR40-F  
5’- agtcctcgtcacacatattg -3’ 
GPR40-R  
5'- aatgcctccaatgtggatag -3' 
Katsuma et al., 2005 
GPR41  GPR 41-F  
5’- ttcttgcagccacactgctc -3’ 
GPR 41-R  
5'- gcccaccacatgggacatat -3' 
Brown et al. 2003 
GPR120 GPR 120-F  
5'- gcataggagaaatctcatgg -3, 
GPR 120-R  
5'- gagttggcaaacgtgaaggc -3' 
Katsuma et al., 2005 
LbLMA1/R-161 LbLMA1/R-161-F 
5'- ctcaaaactaaacaaagtttc -3' 
LbLMA1/R-161-R 
5'-ctcgtacttgtacacaccgcccgtca -3' 
Dubernet et al., 2002 
16SrRNA 16SrRNA-F 
5'- ccagagtttgatcmtggctcag -3' 
16SrRNA-R 
5'- cggttaccttgttacgacttcacc -3' 
Turner et al., 1999; 
Rogall et al., 1990 
Phe Phe-F 
5'- tatttcaaaattgcraaacgr -3'; 
Phe-R 
5'- cccwgcwcgtgatatgca -3’ 
Naser et al., 2007 
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Supplementary Table 1: TLR Gene Array: changes in gene expression in 
pGIP/Neo STC-1 cells following co-culture with L. rhamnosus. Note:- Positive 
fold change indicates up-regulation. Negative fold change indicates down-
regulation. *P<0.05. 
 
Genes Refseq Fold Changes 
  
 Genes Refseq Fold Changes 
  
Toll-like receptors  NF kappa B pathway Tlr1 NM_030682 1.84   Ccl2 NM_011333 1.16  Tlr2 NM_011905 -9.71 *  Chuk NM_007700 4.38 * Tlr3 NM_126166 -1.75   Csf2 NM_009969 2.02 * Tlr4 NM_021297 -2.79 *  Csf3 NM_009971 -4.62 * Tlr5 NM_016928 -1.06   Agfg1 NM_010472 1.31  Tlr6 NM_011604 2.02 *  Ikbkb NM_010546 -1.27  Tlr7 NM_133211 2.02 *  Il1a NM_010554 -3.20 * Tlr8 NM_133212 2.02 *  Il1b NM_008361 3.41 * Tlr9 NM_031178 2.02 *  Il1r1 NM_008362 1.88  Muc13 NM_010739 2.50 *  Il2 NM_008366 2.02 * Adaptors & interacting proteins  Il6 NM_031168 -1.72  Btk NM_013482 -2.48 *  Il10 NM_010548 -1.73  Cd14 NM_009841 17.52 *  Il12a NM_008351 2.02 * Hmgb1 NM_010439 4.93 *  Map3k1 NM_011945 -
 
* 
Hras1 NM_008284 1.14   Nfkb1 NM_008689 1.88  Hspa1a NM_010479 3.18 *  Nfkb2 NM_019408 -2.64 * Hspd1 NM_010477 3.53 *  Nfkbia NM_010907 1.43  Lta NM_010735 1.45   Nfkbib NM_010908 2.17 * Ly86 NM_010745 2.03 *  Nfkbil1 NM_010909 -7.89 * Ly96 NM_016923 -1.15   Nfrkb NM_172766 -
 
* 
Mapk8ip3 NM_013931 1.57   Rel NM_009044 -4.72 * Myd88 NM_010851 -23.41 *  Rela NM_009045 1.06  Peli1 NM_023324 -1.09   Tnf NM_013693 -
 
* 
Pglyrp1 NM_009402 -12.99 *  Tnfaip3 NM_009397 -
 
* 
Ripk2 NM_138952 1.83   Tnfrsf1a NM_011609 1.50  Ticam1 NM_174989 -21.69 *  Tradd NM_001033161 2.07 * Ticam2 NM_173394 1.63   JNK/p38 pathway Tirap NM_054096 1.75   Elk1 NM_007922 -1.62  Tollip NM_023764 2.02 *  Fos NM_010234 -1.01  Effectors     Jun NM_010591 -
 
* 
Casp8 NM_009812 3.73 *  Map2k3 NM_008928 5.82 * Fadd NM_010175 1.41   Map2k4 NM_009157 2.04 * Irak1 NM_008363 1.67   Mapk8 NM_016700 -1.73  Irak2 NM_172161 -1.23   Mapk9 NM_016961 1.07  Map3k7 NM_172688 -1.18   NF/IL6 pathway Nr2c2 NM_011630 -4.89 *  Cebpb NM_009883 1.28  Ppara NM_011144 1.35   Clec4e NM_019948 2.02 * Eif2ak2 NM_011163 -2.31 *  Il6ra NM_010559 -
 
* 
Ube2n NM_080560 1.92   Ptgs2 NM_011198 -2.41 * Ube2v1 NM_023230 1.50   Adaptive Immunity IRF pathway  Cd80 NM_009855 -2.71 * Cxcl10 NM_021274 -1.12   Cd86 NM_019388 2.02 * Ifnb1 NM_010510 2.02 *  Traf6 NM_009424 -6.14 * Ifng NM_008337 2.02 *      Irf1 NM_008390 -1.59       Irf3 NM_016849 -3.14 *      Tbk1 NM_019786 -1.44       
